Fortrea Holdings Inc. (NASDAQ:FTRE) is among the low-cost shares to purchase for the subsequent 5 years. On October 2, Barclays raised the agency’s value goal on Fortrea to $8 from $6, whereas holding an Underweight score as a part of a Q3 2025 preview for the life science instruments and diagnostics group. Earlier in Q2, Fortrea Holdings made a quarterly income of $710.3 million, which was up 7.23% year-over-year.
The corporate additionally achieved an Adjusted EBITDA of $54.9 million and an adjusted web revenue per diluted share of $0.19, which led administration to lift its full-year 2025 income steering to a variety of $2.6 to $2.7 billion, whereas affirming its Adjusted EBITDA steering.
However regardless of this development, Fortrea recorded a GAAP web lack of $374.9 million, or $4.14 per diluted share as a consequence of a considerable non-cash goodwill impairment cost of $309.1 million. Fortrea’s backlog stood at $7.547 billion. In Q2, the corporate affirmed that its cost-saving initiatives stay on observe.
Fortrea Holdings Inc. (NASDAQ:FTRE) is a contract analysis group that gives biopharmaceutical product & medical gadget improvement options to pharmaceutical, biotechnology, and medical gadget prospects.
Whereas we acknowledge the potential of FTRE as an funding, we imagine sure AI shares supply higher upside potential and carry much less draw back threat. Should you’re on the lookout for a particularly undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring pattern, see our free report on the finest short-term AI inventory.
READ NEXT: 30 Shares That Ought to Double in 3 Years and 11 Hidden AI Shares to Purchase Proper Now.
Disclosure: None. This text is initially revealed at Insider Monkey.
